Biogen’s Strategic Pivot Faces Critical Test with New Alzheimer’s Therapy

Biogen Inc. finds itself at a crucial inflection point. The pharmaceutical giant is navigating a deliberate shift away from its core multiple sclerosis business, which continues its gradual decline, and toward new growth pillars in immunology and rare diseases. Under the leadership of CEO Christopher Viehbacher, this strategic overhaul represents a significant bet on the company’s future. The central question for investors is whether the recently approved subcutaneous Alzheimer’s treatment, LEQEMBI IQLIK, can deliver the necessary growth catalyst or if Biogen will fall behind in the intensely competitive Alzheimer’s therapeutic landscape.

The company’s second-quarter 2025 results provide a solid foundation for this transition, having surpassed expectations with earnings per share of $5.47 and revenue reaching $2.65 billion. Despite this financial Read more...